Trial Information

Summary: Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery

This research is being done because even with the most aggressive after-surgery treatment with chemotherapy, many people still have the lung cancer recur (come back).

The purpose of this study is to determine if adding the new drug bevacizumab to chemotherapy improves the chance for cure for patients who have had surgery for the removal of the lung cancer. We will compare the effects (good and bad) of adding bevacizumab to chemotherapy with standard chemotherapy alone on you and your lung cancer to see which is better at preventing the cancer from coming back.

Disease Characteristics:

• Diagnosis of stage IB-IIIA (T2-3 N0, T1-3 N1, T1-3 N2) non-small cell lung cancer (NSCLC)
• Patients with stage IB disease must have tumors measuring > 4 cm
• Must have undergone complete resection of NSCLC within the past 6-12 weeks
• Accepted types of resection include any of the following:
  • Lobectomy
  • Sleeve lobectomy
  • Bilobectomy
  • Pneumonectomy
• No resection by segmentectomy or wedge resection

For more information please go to http://www.valleyhealth.com/VH_ps_Oncology Clinical.asp

If you would like to learn more about participating in this study, please send an e-mail message using the form below.